Embolism and Thrombosis: Clinical Trials

3,285 trials for Embolism and Thrombosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1856 completed, 560 unknown, 328 recruiting, 241 terminated. 762 Not applicable, 452 Phase 3, 330 Phase 4, 320 Phase 2, 159 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable762Completed 406, Unknown 127, Recruiting 91, Terminated 53, Not yet recruiting 30, Active not recruiting 24, Withdrawn 23, Enrolling by invitation 4, Suspended 4
Phase 3452Completed 280, Terminated 57, Unknown 49, Recruiting 37, Not yet recruiting 12, Withdrawn 8, Active not recruiting 7, Enrolling by invitation 1, Suspended 1
Phase 4330Completed 186, Unknown 50, Terminated 36, Recruiting 26, Not yet recruiting 12, Withdrawn 12, Active not recruiting 5, Enrolling by invitation 3
Phase 2320Completed 196, Terminated 47, Unknown 37, Recruiting 19, Withdrawn 13, Not yet recruiting 4, Active not recruiting 2, Enrolling by invitation 2
Phase 1159Completed 113, Unknown 15, Terminated 12, Recruiting 10, Withdrawn 5, Active not recruiting 2, Not yet recruiting 2
Early Phase 127Completed 18, Recruiting 3, Terminated 2, Unknown 2, Not yet recruiting 1, Withdrawn 1

Follow Embolism and Thrombosis: new trials by email Literature Review of Embolism and Thrombosis trials Research Report on Embolism and Thrombosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications
Freeze-Dried Plasma, Conventional Plasma - Thromboembolic Event, FDP
Phase 4Not yet recruitingTeleflex8672027-10-012026-09-30
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC) - Venous Thromboembolism, Children Under 2 Years
Not yet recruitingBayer8502027-09-012026-10-02
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
Enoxaparin - Venous Thromboembolism (VTE)
Phase 3Not yet recruitingJohns Hopkins All Children's Hospital8022027-04-152026-05-26
SAFELY RULING OUT DEEP VEIN THROMBOSIS IN PREGNANCY WITH THE LEFt SCORE AND TRIMESTER-ADJUSTED D-DIMER CUTOFFS (the PREG-DVT Study): A PROSPECTIVE COHORT STUDY.
D-dimer - Pregnancy Related, Deep Vein Thrombosis
Not applicableNot yet recruitingMarc Righini3302027-04-012026-10-21
Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients
Quantra System - Pediatric, Coagulation
Not yet recruitingHemoSonics LLC2402027-03-152026-09-17
Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator - Pulmonary Embolism, Right Ventricular Dysfunction
SuspendedBrigham and Women's Hospital602027-01-012026-01-21
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
BOTOX INJECTION - Buerger Disease, Raynaud Syndrome
Phase 3Not yet recruitingUniversity Hospital, Toulouse82027-01-012026-07-23
Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome
Vitamin K Antagonist - Drug, Anticoagulant Therapy Discontinuation - Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris2342026-12-012026-10-15
Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study
Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT)
Not yet recruitingInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval1002026-12-012026-03-24
LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus
Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin - Left Ventricular Thrombus
Phase 2Not yet recruitingQueen Mary University of London1202026-12-012026-02-27
Investigating a Personalized Approach to Anti-Platelet Therapy
Genotyping guided therapy for anti-platelet management - High Risk Bleeding
Phase 4Not yet recruitingOttawa Heart Institute Research Corporation17602026-12-012026-11-03
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Experimental group: ticagrelor, Control group: placebo - Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Phase 3Not yet recruitingUniversity Hospital, Toulouse2742026-11-242026-11-06
Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study
Delayed Un-gated CT Scan for Left Atrial Appendage Thrombus, Delayed Gated CT Scan for Left Atrial Appendage Thrombus - Atrial Fibrillation (AF), Pulmonary Embolism (PE)
Not applicableNot yet recruitingNorthwell Health602026-11-012026-10-26
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
edoxaban, Apixaban - Venous Thromboembolism, Active Cancer
Phase 4Not yet recruitingSamsung Medical Center23002026-11-012026-10-01
Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)
blood sampling for measuring anti-Xa activity, measurement of anti-XA activity - Congenital Heart Disease, Unfractionated Heparin
Not applicableNot yet recruitingCentre Hospitalier Universitaire de la Réunion222026-11-012026-09-21
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
Alteplase, Standard Anticoagulation - Pulmonary Embolism
Phase 3Not yet recruitingChina National Center for Cardiovascular Diseases2702026-11-012026-11-04
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Thrombolysis Catheter - Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Not applicableNot yet recruitingFlow Medical Solutions, Inc.202026-11-012026-11-06
Regulation of Platelet Function in Older Patients With Atrial Fibrillation
Atrial Fibrillation, Thrombotic Risk
Not yet recruitingUniversity of Michigan502026-11-012026-11-09
Viscoelastic Coagulation Monitoring for Early Identification of Sepsis: The VISION II Study
Viscoelastic Coagulation Monitor (VCM) testing - Sepsis, Infection
Not yet recruitingHellenic Institute for the Study of Sepsis4002026-11-012026-11-10

Showing 20 of 3285. Sign in to see all of them.

Narrower conditions

Thrombosis (955)  ·  Pulmonary Embolism (783)  ·  Venous Thrombosis (763)  ·  Venous Thromboembolism (698)  ·  Thromboembolism (288)  ·  Retinal Vein Occlusion (276)  ·  Hemorrhage (178)  ·  Atrial Fibrillation (163)  ·  Stroke (154)  ·  Macular Edema (113)  ·  Neoplasms (110)  ·  Cardiovascular Diseases (102)  ·  Embolism (94)  ·  COVID-19 (92)  ·  Raynaud Disease (80)

Broader conditions

Vascular Diseases (3255)  ·  Cardiovascular Diseases (3183)  ·  Thrombosis (1123)  ·  Respiratory Tract Diseases (904)  ·  Lung Diseases (875)  ·  Pathological Conditions, Signs and Symptoms (861)  ·  Embolism (785)  ·  Pathologic Processes (767)  ·  Thromboembolism (739)  ·  Heart Diseases (395)  ·  Nervous System Diseases (377)  ·  Venous Thrombosis (342)  ·  Central Nervous System Diseases (304)  ·  Brain Diseases (294)

Interventions

Rivaroxaban (191)  ·  Enoxaparin (175)  ·  Warfarin (114)  ·  apixaban (113)  ·  Aspirin (86)  ·  Heparin (69)  ·  Heparin, Low-Molecular-Weight (62)  ·  Ranibizumab (60)  ·  Dalteparin (59)  ·  Blood Specimen Collection (55)  ·  Dabigatran (55)  ·  Fondaparinux (42)  ·  Clopidogrel (40)  ·  Tissue Plasminogen Activator (40)  ·  edoxaban (38)

Sponsors

Bayer (77)  ·  Assistance Publique - Hôpitaux de Paris (44)  ·  Brigham and Women's Hospital (39)  ·  Bristol-Myers Squibb (39)  ·  University Hospital, Brest (38)  ·  Ottawa Hospital Research Institute (32)  ·  Assiut University (31)  ·  Boehringer Ingelheim (29)  ·  Sanofi (28)  ·  McMaster University (27)  ·  National Heart, Lung, and Blood Institute (NHLBI) (23)  ·  GlaxoSmithKline (21)  ·  Novartis Pharmaceuticals (21)  ·  HemoSonics LLC (19)  ·  Insel Gruppe AG, University Hospital Bern (19)

Countries

United States (944)  ·  France (459)  ·  Canada (316)  ·  China (279)  ·  Italy (248)  ·  Germany (239)  ·  United Kingdom (209)  ·  Spain (197)  ·  Netherlands (170)  ·  Denmark (152)  ·  Switzerland (138)  ·  Belgium (135)  ·  Austria (130)  ·  Sweden (129)  ·  Poland (126)

Top investigators

Shirley Wang, PhD, ScM (7)  ·  Samuel Z Goldhaber, MD (6)  ·  Samuel Z. Goldhaber, MD (6)  ·  Gregory Piazza, MD, MS (5)

Results publications

PMID 33779986, PMID 33337539, PMID 35244208, PMID 39968829, PMID 33502773, PMID 38189593, PMID 35570249, PMID 36912792, PMID 37591523, PMID 40163217, PMID 24081972, PMID 28762617, PMID 33086312, PMID 34622445, PMID 36413425, PMID 37929840, PMID 22371186, PMID 22429800, PMID 22709460, PMID 22863355, PMID 23425163, PMID 23629822, PMID 25698905, PMID 27807306, PMID 28617144, PMID 29976287, PMID 31420317, PMID 32633861, PMID 32657973, PMID 34127618, PMID 34172290, PMID 34597414, PMID 34878173, PMID 38941511, PMID 15319720, PMID 15842354, PMID 17855670, PMID 18190818, PMID 19017588, PMID 19348685, PMID 19920268, PMID 20696966, PMID 20860504, PMID 21128814, PMID 22172244, PMID 22315264, PMID 22429908, PMID 22449293, PMID 22995531, PMID 23013426

NIH funding

2014 (11), 2018 (11), 2009 (10), 2015 (10), 2016 (10), 2019 (9), 2023 (9), 2025 (8), 2017 (7), 2005 (6), 2008 (6), 2004 (3), K23HL132054 (2), R01HL114405 (2), 1UG1EY026876-01A1 (1)